Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) EBITDA Margin: 2022-2025

Historic EBITDA Margin for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to 0.56%.

  • Addex Therapeutics' EBITDA Margin fell 1112589.00% to 0.56% in Q2 2025 from the same period last year, while for Jun 2025 it was 1.39%, marking a year-over-year decrease of 330147.00%. This contributed to the annual value of -726.94% for FY2024, which is 152539.00% down from last year.
  • Latest data reveals that Addex Therapeutics reported EBITDA Margin of 0.56% as of Q2 2025, which was down 87.80% from 4.55% recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' EBITDA Margin registered a high of 13,535.27% during Q4 2023, and its lowest value of -21,942.11% during Q4 2024.
  • Moreover, its 3-year median value for EBITDA Margin was -466.14% (2023), whereas its average is -338.40%.
  • Per our database at Business Quant, Addex Therapeutics' EBITDA Margin soared by 1,692,126bps in 2023 and then tumbled by 3,547,738bps in 2024.
  • Over the past 4 years, Addex Therapeutics' EBITDA Margin (Quarterly) stood at -3,385.99% in 2022, then spiked by 1,692,126bps to 13,535.27% in 2023, then crashed by 3,547,738bps to -21,942.11% in 2024, then tumbled by 1,112,589bps to 0.56% in 2025.
  • Its EBITDA Margin stands at 0.56% for Q2 2025, versus 4.55% for Q1 2025 and -21,942.11% for Q4 2024.